Progress and Promise in Prostate Cancer
The Year in mCRPC – An Unobjective Look at Some of 2018’s Best Papers
RB, or Not RB: That is the Question!
Apollo 14 and the Lessons from Fractures
In Search of the Ultimate Cause of Cancer Death and Survival
My institution, the University of Minnesota, recently launched a “Medical Discovery Team on the Biology of Aging” a program that brings together clinicians,
The Positive in the Negative
Or, I might be working on the design of the phase III study of BEZ235 in mCRPC, or the use of AMG-102 plus mitoxantrone in patients following docetaxel for mCRPC.
New Metastatic Prostate Cancer? First, Take a Deep BREATH
Abiraterone + Enzalutamide: Is It Love or Just a PLATOnic Relationship?
How Do We Know When What We Are Doing Isn't Working?
Landmarks, Surrogates and Strategies for Accelerating Clinical Trial Results
Good Abi, Bad Abi
Genomically Guided Therapy for Prostate Cancer: Promise Unfulfilled, Misguided or Too Early to Call?
Wherefore Art Thou, Provenge?
A meditation on the need and utility for Sip T in 2018. On a nearly weekly basis I am confronted by the question of whether I should be giving a patient Sipuleucel T. I still use it, but not in all my CRPC patients, and I like to think of this therapy as having a reasonable benefit for patients - who are at an early point in the CRPC spectrum. I will explain but first let’s review the data and its limitations.
Five Ways That Writing a Book Improved My Care of CRPC Patients
Non-Metastatic CRPC: The Five Essentials
Riding High on MSI
Ok, now that I have your attention, let’s talk about the science, the clinical care and the implications for the field.
But first, a brief case. Consider my patient Arnold (not his real name). He is a 68-year old man who underwent radical prostatectomy in 2011.